C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Tuesday, down -3.35% from the previous trading day, before settling in for the closing price of $2.09. Over the past 52 weeks, CCCC has traded in a range of $1.09-$4.26.
During the last 5-year period, the sales drop of Healthcare Sector giant was -8.92%. While this was happening, its average annual earnings per share was recorded 7.51%. With a float of $78.37 million, this company’s outstanding shares have now reached $96.91 million.
Let’s determine the extent of company efficiency that accounts for 110 employees.
C4 Therapeutics Inc (CCCC) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 19.13%, while institutional ownership is 57.44%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.49 earnings per share (EPS), lower than consensus estimate (set at -0.45) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.69% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 5.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Looking closely at C4 Therapeutics Inc (NASDAQ: CCCC), its last 5-days average volume was 3.5 million, which is a jump from its year-to-date volume of 1.62 million. As of the previous 9 days, the stock’s Stochastic %D was 10.18%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 5.23%, which indicates a significant decrease from 10.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was lower than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.43, while its 200-day Moving Average is $2.08. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $2.08. Second resistance stands at $2.15. The third major resistance level sits at $2.22. If the price goes on to break the first support level at $1.94, it is likely to go to the next support level at $1.87. Should the price break the second support level, the third support level stands at $1.80.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
The company with the Market Capitalisation of 195.77 million has total of 96,914K Shares Outstanding. Its annual sales at the moment are 35,580 K in contrast with the sum of -105,320 K annual income. Company’s last quarter sales were recorded 11,230 K and last quarter income was -32,170 K.
